



Sanofi joins Together for Sustainability (TfS) initiative to enhance the sustainability practices within its global supply chains

- The TfS initiative involves independent experts carrying out assessments and audits of suppliers avoiding the need for each of the members to conduct their own –

- Other benefits include quality assurance, a reduction in the bureaucratic burden for suppliers and the lowering of risks in relation to sustainability requirements -

Paris, France - May 3, 2016 - [Sanofi](#) joins Together for Sustainability (TfS) initiative to enhance the sustainability practices within its global supply chains. Sanofi is the first French- based healthcare company to become part of this growing consortium of companies supporting sustainable supply chains. This initiative is based on established principles such as the United Nations Global Compact and the Responsible Care Global Charter®.

By joining TfS, Sanofi is underscoring the importance of supplier management as part of its corporate responsibility. The objective of TfS which was established in 2011 is to develop a global supplier engagement program to assess, audit and improve sustainability practices within the supply chains of the chemical industry.

The TfS initiative involves independent experts carrying out assessments and audits of suppliers; they will be assessed on environmental, health and safety aspects, labor and human rights as well as ethical company management.

The results of Assessments and Audits will be shared within the network, offering both customers and suppliers efficiency advantages. Instead of individual assessment processes with different customers, in the future suppliers can undergo a single audit or assessment shared within TfS on a web-based collaborative platform.

“We, at Sanofi, are mobilized on a daily basis to create value for our patients and our ecosystem. Our number one priority is to bring medicines and vaccines to patients around the world. We manage 13,5 B€ of spends and more than +100 000 suppliers in 80 countries. By joining TfS and working closely with its members, we will meet world class standards and deliver efficiency across our global end-to end process including our suppliers. It is our duty to ensure that our suppliers are acting in a socially responsible manner”, said Karim Vissandjee, Senior Vice President, Sanofi Business Services.

More information is available on both the [Sanofi/Suppliers](#) and the [Corporate Social Responsibility](#) websites.

About Sanofi Business Services

Sanofi Business Services (SBS) is a global cross-functional organization that will support our internal and external partners, enabling the Group’s profitable and sustainable growth. SBS



ambition is to create best-in-class service delivery with enhanced quality, efficiency and agility through value creation and flawless execution.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Meril. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#)).

About TfS

TfS is a joint initiative of chemical companies for sustainable supply chains. It was founded in 2011, to develop and implement a global program to assess, audit and improve sustainability practices within the supply chains of the chemical industry. Currently it has 17 member companies worldwide with two more in onboarding and intends to grow globally; www.tfs-initiative.com.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Mai Tran

Tél.: +33 (0) 1.53.77.49.86

mr@sanofi.com